Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma

Por de Gast, G C, Batchelor, D, Kersten, M J, Vyth-Dreese, F A, Sein, J, van de Kasteele, W F, Nooijen, W J, Nieweg, O E, Waal, M A de, Boogerd, W
Publicado em 2003